Daily Ards Research Analysis
Analyzed 2 papers and selected 2 impactful papers.
Summary
Two studies highlight advances across critical care physiology and rare disease diagnostics. A randomized physiological study shows inhaled nitric oxide improves V/Q matching in moderate-to-severe ARDS using bedside EIT. A neonatal case report demonstrates that rapid whole-genome sequencing enables early diagnosis and intervention in Menke-Hennekam syndrome.
Research Themes
- ARDS physiology and bedside monitoring with EIT
- Personalized adjunctive therapies (inhaled nitric oxide)
- Rapid genomic diagnostics in neonatal rare disorders
Selected Articles
1. Effects of inhaled nitric oxide on ventilation/perfusion mismatch assessed by electrical impedance tomography in intubated patients with moderate-to-severe ARDS: a prospective physiological study.
In a single-center randomized physiological trial of 40 intubated moderate-to-severe ARDS patients, 24-hour iNO improved V/Q matching, reducing EIT-measured dead space and shunt (between-group P<0.001), with parallel improvements in oxygenation. Findings support EIT-guided personalization of iNO as an adjunct.
Impact: Provides direct, bedside mechanistic evidence that iNO improves oxygenation via V/Q matching quantified by EIT, bridging physiology and personalized care in ARDS.
Clinical Implications: iNO may be selectively used in ARDS patients with demonstrable V/Q mismatch, with EIT as a monitoring tool to tailor therapy; however, absence of clinical outcome data warrants cautious application.
Key Findings
- iNO improved V/Q matching at 24 hours versus control, measured noninvasively by EIT.
- Reductions in EIT-estimated dead space and shunt were significantly greater with iNO (between-group P<0.001).
- Improved gas exchange accompanied V/Q improvements, with increased oxygenation over 24 hours.
Methodological Strengths
- Randomized controlled design with prospective physiological endpoints.
- Use of bedside EIT to directly quantify regional V/Q-related metrics.
Limitations
- Single-center, small sample size limits generalizability.
- Short 24-hour observation with surrogate outcomes; retrospective trial registration.
- No clinical outcome endpoints (e.g., mortality, ventilator-free days).
Future Directions: Conduct multicenter, adequately powered RCTs testing EIT-guided iNO strategies with patient-centered outcomes; evaluate longer exposure and biomarker/inflammation trajectories.
BACKGROUND: Inhaled nitric oxide (iNO) improves oxygenation in acute respiratory distress syndrome (ARDS), but its precise physiological effects on ventilation-perfusion (V/Q) matching and inflammation over 24 h remain to be fully elucidated. To determine the effect of iNO on V/Q matching, gas exchange, and systemic inflammatory response in mechanically ventilated patients with moderate-to-severe ARDS. METHODS: We conducted a prospective, single-center, randomized controlled trial in 40 mechanically ventilated patients with moderate-to-severe ARDS (PaO RESULTS: Forty patients were randomized (20 per group). At 24 h, the iNO group showed a significantly greater improvement in V/Q matching compared to the control group. The magnitude of reduction in both EIT-measured dead space (between-group difference, P < 0.001) and shunt (between-group difference, P < 0.001 was significantly larger in the iNO group. This physiological improvement was reflected in gas exchange: the median PaO CONCLUSIONS: In patients with moderate-to-severe ARDS, 24-hour administration of inhaled nitric oxide significantly improves oxygenation by enhancing ventilation-perfusion matching. This effect is driven by a marked reduction in both EIT-measured shunt and dead space. This study provides a direct mechanistic rationale for iNO's physiological effects and supports the potential of using EIT to guide a more personalized therapeutic approach. TRIAL REGISTRATION: Clinicaltrials.gov; Unique identifier: ChiCTR2500113100; Retrospectively registered; Registration date: 25 November 2025.
2. From weeks to hours: rapid whole-genome sequencing reduces diagnostic odyssey in Menke-Hennekam syndrome-a case report.
Trio rapid WGS in a Han Chinese neonate with nonspecific features identified a de novo CREBBP missense variant (c.5570A>C; p.His1857Pro) within 72 hours, enabling neonatal diagnosis of MKHK-ID4. Early targeted interventions followed and were associated with notable developmental gains at 15 months.
Impact: Illustrates the clinical utility of rapid trio WGS to shorten the diagnostic timeline for rare syndromic disorders and trigger timely multidisciplinary care.
Clinical Implications: Supports considering rapid trio WGS for neonates with syndromic features and diagnostic uncertainty to expedite targeted interventions and care planning.
Key Findings
- Rapid trio WGS yielded results within 72 hours at 23 days of age, enabling neonatal diagnosis of MKHK-ID4.
- A novel de novo CREBBP missense variant (c.5570A>C; p.His1857Pro) was identified and classified as likely pathogenic, confirmed absent in parents by Sanger sequencing.
- Early interventions (hearing aid fitting, comprehensive rehabilitation, surgical planning) were initiated and coincided with developmental improvements at 15 months.
Methodological Strengths
- Use of rapid trio WGS with parental confirmation by Sanger sequencing.
- Detailed phenotyping and longitudinal follow-up to 15 months.
Limitations
- Single-patient case report limits generalizability and causal inference.
- Functional validation of the variant and long-term outcomes are not provided.
Future Directions: Prospective evaluations of rapid WGS in neonatal diagnostic workflows for syndromic presentations; functional studies of novel CREBBP variants and long-term outcome registries.
BACKGROUND: Menke-Hennekam syndrome (MKHK) is a rare autosomal dominant disorder caused by mutations in the CREBBP and EP300 genes. The absence of established diagnostic criteria and non-specific clinical manifestations complicate timely diagnosis and management. This report presents a case of MKHK in which early diagnosis and intervention were achieved through the application of rapid whole-genome sequencing (rWGS), a tool that offers superior speed and genomic coverage compared to whole-exome sequencing (WES). CASE PRESENTATION: This case report describes a male Han Chinese neonate who presented at birth (0 days) with intrauterine growth restriction, respiratory distress, and feeding difficulties. During follow-up, he developed hearing loss and demonstrated global developmental delay. Clinical examination revealed craniofacial dysmorphism. Trio rWGS was performed in the neonatal period, with results returned within 72 h of sample submission at 23 days of age. Trio rWGS identified a de novo missense variant in the CREBBP gene (c.5570A > C, p.His1857Pro). Sanger sequencing confirmed its absence in both parents, and the variant was classified as likely pathogenic despite no prior documented cases. Based on integrated genetic and clinical findings, a neonatal diagnosis of MKHK-ID4 was established. Following this diagnosis, early targeted interventions were initiated, including hearing aid fitting, enrollment in a comprehensive rehabilitation program, and planning for necessary surgical corrections. Significant developmental improvement was observed at the 15-month follow-up assessment. CONCLUSION: In this case, rWGS facilitated a neonatal diagnosis of MKHK-ID4 and enabled early multidisciplinary intervention during a critical neurodevelopmental window. This experience suggests that such an approach may contribute to improved developmental outcomes in this rare disorder, though further studies are required to confirm its broader applicability and long-term benefits.